89 related articles for article (PubMed ID: 24424314)
1. Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.
Le Saux O; You B; Freyer G
Clin Breast Cancer; 2014 Jun; 14(3):e89-94. PubMed ID: 24424314
[No Abstract] [Full Text] [Related]
2. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
3. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
5. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
7. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Huemer F; Gampenrieder SP; Schlattau A; Greil R
Clin Breast Cancer; 2014 Feb; 14(1):e17-20. PubMed ID: 24246725
[No Abstract] [Full Text] [Related]
8. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Farhat MH; El-Saghir NS; Shamseddine AI
Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
[TBL] [Abstract][Full Text] [Related]
9. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
[TBL] [Abstract][Full Text] [Related]
10. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
11. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
12. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
Yardley DA; Daniel D; Stipanov M; Drosick DR; Mainwaring M; Peyton J; Shastry M; Hainsworth JD
Cancer Invest; 2010 Oct; 28(8):865-71. PubMed ID: 20690802
[TBL] [Abstract][Full Text] [Related]
14. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
Karachaliou N; Saloustros E; Vamvakas L; Mavroudis D; Georgoulias V
Ann Oncol; 2010 Aug; 21(8):1729-1730. PubMed ID: 20601370
[No Abstract] [Full Text] [Related]
15. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.
Āboliņš A; Vanags A; Trofimovičs G; Miklaševičs E; Gardovskis J; Štrumfa I
Pol J Pathol; 2011; 62(1):65-8. PubMed ID: 21574108
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of breast cancer: toward the individualization of therapy.
Chang JC; Hilsenbeck SG; Fuqua SA
Cancer Invest; 2009 Aug; 27(7):699-703. PubMed ID: 19637041
[No Abstract] [Full Text] [Related]
17. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
[No Abstract] [Full Text] [Related]
18. Personalizing therapy for metastatic breast cancer.
Morris PG; Hudis CA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1223-6. PubMed ID: 19761426
[TBL] [Abstract][Full Text] [Related]
19. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
20. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
